Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2014

01-10-2014 | Original Article

Serum Alanine Aminotransferase Independently Correlates with Intrahepatic Triglyceride Contents in Obese Subjects

Authors: Zheng Chen, Cheng-Kun Han, Ling-Ling Pan, Hui-Jie Zhang, Zhi-Min Ma, Zhu-Feng Huang, Shi Chen, Xiong-Jie Zhuang, Zhi-Bin Li, Xiao-Ying Li, Xue-Jun Li, Shu-Yu Yang

Published in: Digestive Diseases and Sciences | Issue 10/2014

Login to get access

Abstract

Background and Aim

Liver enzymes including serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT) are well recognized as surrogate makers reflecting non-alcoholic fatty liver disease (NAFLD). However, the associations of serum ALT, AST and GGT with hepatic lipid contents are not well established. The aim of this study was to investigate the relationship between liver enzymes and intrahepatic triglyceride (IHTG) contents, and explore the feasibility in using liver enzymes to reflect accumulation of IHTG in obese subjects.

Methods

A cross-sectional analysis was conducted in 475 obese adults aged 40–65 years. Anthropometric parameters and blood biochemical indexes including liver enzymes, glucose and lipid profiles were measured. The liver triglyceride contents of subjects were determined by 1H-MRS.

Results

Serum ALT, AST and GGT were positively correlated with IHTG contents (p < 0.01). Serum ALT, AST and GGT levels at the highest quartile of IHTG contents were significantly elevated as compared with those in the lowest quartile (p < 0.01). Multivariate linear regression analysis demonstrated that serum ALT, but not AST or GGT was independently associated with IHTG contents. By logistic regression analysis, the odds ratio for higher IHTG contents was increased by 1.464 times/1 SD increase in serum ALT level after adjusting for multiple confounding factors [OR (95 % CI) 2.464 (1.584–3.834)]. However, these relationships could not be observed between serum AST or GGT with IHTG contents.

Conclusions

Serum ALT level is independently correlated with the hepatic triglyceride contents in obese subjects and more appropriate to be used as a predictor for the degree of NAFLD rather than AST and GGT.
Literature
1.
go back to reference Hoyumpa AM Jr, Green HL, Dunn GD, Schenker S. Fatty liver: biochemical and clinical considerations. Am J Dig Dis. 1975;20:1142–1170.PubMedCrossRef Hoyumpa AM Jr, Green HL, Dunn GD, Schenker S. Fatty liver: biochemical and clinical considerations. Am J Dig Dis. 1975;20:1142–1170.PubMedCrossRef
2.
go back to reference Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic steatohepatitis C: design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.PubMedCrossRef Kleiner DE, Brunt EM, Van Natta M, et al. Nonalcoholic steatohepatitis C: design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.PubMedCrossRef
3.
go back to reference Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923.PubMedCrossRef Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923.PubMedCrossRef
4.
go back to reference Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419.PubMedCrossRef Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419.PubMedCrossRef
5.
go back to reference Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case–control study. Hepatology. 2000;32:689–692.PubMedCrossRef Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case–control study. Hepatology. 2000;32:689–692.PubMedCrossRef
6.
go back to reference Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: hepatocellular carcinoma. Gastroenterology. 2002;123:134–140.PubMedCrossRef Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: hepatocellular carcinoma. Gastroenterology. 2002;123:134–140.PubMedCrossRef
7.
go back to reference Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40:S5–S10.PubMed Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40:S5–S10.PubMed
8.
go back to reference Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57:1378–1383.PubMedCrossRef Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57:1378–1383.PubMedCrossRef
9.
go back to reference Scheig R. Evaluation of tests used to screen patients with liver disorders. Prim Care. 1996;23:551–560.PubMedCrossRef Scheig R. Evaluation of tests used to screen patients with liver disorders. Prim Care. 1996;23:551–560.PubMedCrossRef
10.
go back to reference Teschke R, Koch T. Biliary-excretion of gamma-glutamyl-transferase—selective enhancement by acute ethanol administration. Biochem Pharmacol. 1986;35:2521–2525.PubMedCrossRef Teschke R, Koch T. Biliary-excretion of gamma-glutamyl-transferase—selective enhancement by acute ethanol administration. Biochem Pharmacol. 1986;35:2521–2525.PubMedCrossRef
11.
go back to reference Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17:1136–1143.PubMedCrossRef Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17:1136–1143.PubMedCrossRef
12.
go back to reference Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17:S186–S190.PubMedCrossRef Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17:S186–S190.PubMedCrossRef
13.
go back to reference Tanaka N, Tanaka E, Sheena Y, et al. Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int. 2006;26:956–963.PubMedCrossRef Tanaka N, Tanaka E, Sheena Y, et al. Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int. 2006;26:956–963.PubMedCrossRef
14.
go back to reference Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94:3010–3014.PubMedCrossRef Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94:3010–3014.PubMedCrossRef
15.
go back to reference Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol. 1999;34:85–91.PubMedCrossRef Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol. 1999;34:85–91.PubMedCrossRef
16.
go back to reference Siest G, Schiele F, Galteau MM, et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem. 1975;21:1077–1087.PubMed Siest G, Schiele F, Galteau MM, et al. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem. 1975;21:1077–1087.PubMed
17.
go back to reference Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–967.PubMedCrossRef Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–967.PubMedCrossRef
18.
go back to reference Thamer C, Tschritter O, Haap M, et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res. 2005;37:246–251.PubMedCrossRef Thamer C, Tschritter O, Haap M, et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res. 2005;37:246–251.PubMedCrossRef
19.
go back to reference Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med. 2000;132:112–117.PubMedCrossRef Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med. 2000;132:112–117.PubMedCrossRef
20.
go back to reference Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22:437–443.PubMedCrossRef Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22:437–443.PubMedCrossRef
21.
go back to reference Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study. Hepatology. 2005;42:44–52.PubMedCrossRef Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study. Hepatology. 2005;42:44–52.PubMedCrossRef
22.
go back to reference Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38:485–489.PubMedCrossRef Palmentieri B, de Sio I, La Mura V, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis. 2006;38:485–489.PubMedCrossRef
23.
go back to reference Wong CA, Araneta MRG, Barrett-Connor E, Alcaraz J, Castenada D, Macera C. Probable NAFLD, by ALT levels, and diabetes among Filipino-American Women. Diabetes Res Clin Pract. 2008;79:133–140.PubMedCrossRef Wong CA, Araneta MRG, Barrett-Connor E, Alcaraz J, Castenada D, Macera C. Probable NAFLD, by ALT levels, and diabetes among Filipino-American Women. Diabetes Res Clin Pract. 2008;79:133–140.PubMedCrossRef
24.
go back to reference Omagari K, Kadokawa Y, Masuda JI, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol. 2002;17:1098–1105.PubMedCrossRef Omagari K, Kadokawa Y, Masuda JI, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol. 2002;17:1098–1105.PubMedCrossRef
25.
go back to reference Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology. 2005;128:627–635.PubMedCrossRef Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology. 2005;128:627–635.PubMedCrossRef
26.
go back to reference Yamada J, Tomiyama H, Yambe M, et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis. 2006;189:198–205.PubMedCrossRef Yamada J, Tomiyama H, Yambe M, et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome. Atherosclerosis. 2006;189:198–205.PubMedCrossRef
27.
go back to reference Gunter EW, Lewis BG, Koncikowski SM. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Environmental Health, National Center for Health Statistics; 1996. Gunter EW, Lewis BG, Koncikowski SM. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Environmental Health, National Center for Health Statistics; 1996.
28.
go back to reference Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–9.PubMedCrossRef Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–9.PubMedCrossRef
29.
go back to reference Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J. 2004;328:983C–986C.CrossRef Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. Br Med J. 2004;328:983C–986C.CrossRef
30.
go back to reference Lee JK, Shim JH, Lee HC, et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology. 2010;51:1577–1583.PubMedCrossRef Lee JK, Shim JH, Lee HC, et al. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology. 2010;51:1577–1583.PubMedCrossRef
31.
go back to reference Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47:1360–1369.PubMedCrossRef Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47:1360–1369.PubMedCrossRef
32.
go back to reference Andre P, Balkau B, Vol S, Charles MA, Eschwege E. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: data from the Epidemiological Study on the insulin resistance syndrome (DESIR) cohort. Diabetes Care. 2007;30:2355–2361.PubMedCrossRef Andre P, Balkau B, Vol S, Charles MA, Eschwege E. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: data from the Epidemiological Study on the insulin resistance syndrome (DESIR) cohort. Diabetes Care. 2007;30:2355–2361.PubMedCrossRef
33.
go back to reference Andre P, Balkau B, Born C, Charles MA, Eschwege E, Grp DS. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the DESIR cohort. Diabetologia. 2006;49:2599–2603.PubMedCrossRefPubMedCentral Andre P, Balkau B, Born C, Charles MA, Eschwege E, Grp DS. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the DESIR cohort. Diabetologia. 2006;49:2599–2603.PubMedCrossRefPubMedCentral
34.
go back to reference Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology. 2009;8:S4–S8.PubMed Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Annals of Hepatology. 2009;8:S4–S8.PubMed
Metadata
Title
Serum Alanine Aminotransferase Independently Correlates with Intrahepatic Triglyceride Contents in Obese Subjects
Authors
Zheng Chen
Cheng-Kun Han
Ling-Ling Pan
Hui-Jie Zhang
Zhi-Min Ma
Zhu-Feng Huang
Shi Chen
Xiong-Jie Zhuang
Zhi-Bin Li
Xiao-Ying Li
Xue-Jun Li
Shu-Yu Yang
Publication date
01-10-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3214-3

Other articles of this Issue 10/2014

Digestive Diseases and Sciences 10/2014 Go to the issue